Dermata achieves 50% enrollment in DMT310 Phase 3 STAR-1 clinical trial
PremiumThe FlyDermata achieves 50% enrollment in DMT310 Phase 3 STAR-1 clinical trial
2M ago
Dermata Therapeutics announces exercise of warrants for $2.66M
Premium
The Fly
Dermata Therapeutics announces exercise of warrants for $2.66M
4M ago
Dermata Therapeutics reports Q1 EPS (47c) vs. ($2.27) last year
Premium
The Fly
Dermata Therapeutics reports Q1 EPS (47c) vs. ($2.27) last year
4M ago
Dermata Therapeutics up 93% at $1.18 after DMT410 Japan patent announcement
PremiumThe FlyDermata Therapeutics up 93% at $1.18 after DMT410 Japan patent announcement
9M ago
Dermata Therapeutics issues new patent in Japan for DMT410 program
Premium
The Fly
Dermata Therapeutics issues new patent in Japan for DMT410 program
9M ago
Dermata Therapeutics files to sell 7.19M shares of common stock for holders
Premium
The Fly
Dermata Therapeutics files to sell 7.19M shares of common stock for holders
10M ago
Dermata Therapeutics price target lowered to $1 from $4 at Maxim
PremiumThe FlyDermata Therapeutics price target lowered to $1 from $4 at Maxim
2y ago
Dermata Therapeutics down 49% after results from DMT310 Phase 2 trial
Premium
The Fly
Dermata Therapeutics down 49% after results from DMT310 Phase 2 trial
2y ago
Dermata Therapeutics announces results from DMT310 Phase 2 trial
Premium
The Fly
Dermata Therapeutics announces results from DMT310 Phase 2 trial
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100